Differences in Expression of Genes Related to Steroidgenesis in Abdominal Subcutaneous Adipose Tissue of Pregnant Women with and without PCOS

Neda Emami  
Islamic Azad University

Ashraf Moini  
Royan Institute

Parichehreh Yaghmaei  
Islamic Azad University

Vahid Akbarinejad  
University of Tehran

Maryam Shahhoseini  
Royan Institute

AliReza Alizadeh (✉ alizadehmasouleh@royaninstitute.org)  
Royan Institute  https://orcid.org/0000-0001-7273-9793

Research

Keywords: Polycystic ovary syndrome, subcutaneous adipose tissue, Sex steroid, Mineralocorticoids, Glucocorticoids

DOI: https://doi.org/10.21203/rs.3.rs-87090/v1

License: ☑️ ✖️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** It was hypothesized that steroid-related gene expressions in the adipose tissue (AT) of women are different between women with and without polycystic ovary syndrome (PCOS). However, little information exists regarding pregnant women suffering from PCOS when interrelationships among maternal PCOS, patient’s quality of life and offspring’s health is a consideration issue in health and diseases. Our objectives were to compare the mRNA expression levels of key steroid-converting enzymes in subcutaneous AT of PCOS vs. non-PCOS pregnant women.

**Methods:** The subjects were 48 pregnant women (12 PCOS and 36 non–PCOS women) undergoing cesarean section, from whom abdominal subcutaneous AT samples were retrieved. Expressions of fifteen genes related to steriodogenesis were investigated using quantitative real-time PCR.

**Results:** No significant differences were found with respect to age, BMI (before pregnancy and at delivery day), gestational period and parity among non-PCOS and PCOS pregnant women. Most of the sex steroid-converting genes except 17β-Hydroxysteroid dehydrogenases2 (17BHSD2), were highly expressed on the day of delivery in subcutaneous AT. PCOS patients showed significantly higher mRNA levels of steroidogenic acute regulator (STAR; \( P<0.001 \)), cytochrome P450 monoxygenase (CYP11A1; \( P<0.05 \)), 17α-hydroxylase (CYP17A1; \( P<0.05 \)), and 11β-Hydroxysteroid dehydrogenase (11BHSD1-2; \( P<0.05 \)). The expression of steroid 21-hydroxylase (CYP21) in non-PCOS women was 4-fold higher than for PCOS women (\( P < 0.001 \)). There were no significant differences between relative expression of aromatase cytochrome P450 (CYP19A1), 3β-hydroxysteroid dehydrogenase1-2 (3BHSD1-2), and 17BHSD family (1, 3, 5, 7, and 12) between the two groups.

**Conclusion:** The expression levels of genes related to sex steroids metabolism were similar in age-matched and BMI-matched non-PCOS and PCOS pregnant women at delivery day. However, the alterations in gene expressions involved in glucocorticoids and mineralocorticoid metabolism was shown which warrants further studies regards functional activity. More attention should be given to AT of PCOS mothers that was previously ignored.

1. Introduction

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disease, occurring in 4–18% of adolescents and women of childbearing age depending on factors such as adiposity and diagnostic criteria [1]. Women suffering from PCOS have several health problems such as metabolic syndrome and androgen imbalance. In conditions of female androgen excess such as PCOS, androgens exert metabolically deleterious effects on adipose tissue (AT) function in a depot-specific manner [2]. Most recently, it has been suggested that AT may contain the steroidogenic machinery necessary for the initiation of steroid biosynthesis *de novo* from cholesterol [3].

The composition and the concentration of steroids released into circulation from AT or removed therefrom, are affected by alterations in fat mass and AT functionality [3, 4]. Androgen and cortisol can
modulate adipocyte function and possibly affect the size and distribution of AT [5]. The role of AT in steroid hormone metabolism has been addressed in research driven by the worldwide human epidemic of adiposities and related disturbances in health and fertility e.g. PCOS [6, 7]. Although the amount of androgen or estrogen derived from AT is not large, the abnormal conversion of androgen precursors to both active and inactive forms at the receptor level is important for the pathogenicity of PCOS [8, 9]. Moreover, pathologically increased circulating cortisol concentration is associated with obesity, insulin resistance and PCOS. It is also responsible for the generation of cortisol in AT by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11BHS1), which converts inactive cortisone to active cortisol [10].

Uniquely, Quinkler et al. suggested that high levels of 17β-hydroxysteroid dehydrogenase 5 (17βHSD5: responsible for the conversion of androstenedione to testosterone) in AT may lead to overweight and hyperandrogenism in PCOS women [11]. However, a surprising observation by Mackenzie et al. 2008, was that de novo syntheses of sex steroids, cortisol and aldosterone from cholesterol are not possible in pregnant women on the day of delivery because of the absence of key steroidogenic mRNAs in the AT [12]. Likewise, Lim et al. [1] showed that women with PCOS have increased risk of metabolic syndrome, which is associated with obesity and metabolic features but not with indices of hyperandrogenism. Overall, selectively targeting intra-adipose androgen activation may therefore represent a promising novel therapeutic strategy for women with PCOS [2].

There is increasing understanding on the roles of subcutaneous AT in PCOS women. More recently, Schiffer et al. suggested that adipose androgen generation is increased in subcutaneous AT in women with PCOS [2]. In this regard, it has been reported that only upper body not lower body obesity is associated with menstrual disorders [13]. The critical roles of subcutaneous AT in women was confirmed by Kuchenbecker et al. who showed that the subcutaneous abdominal AT and not the intra-abdominal fat compartment is associated with anovulation in women with obesity and infertility [14]. Moreover, Yucel et al. reported that free testosterone level is positively correlated with subcutaneous fat mass in the arms in women with PCOS [15]. Overall, previous studies support the “adipose tissue expandability” hypothesis, which proposes that overfilling of subcutaneous AT leads to the lipotoxic state, characterized by elevated free fatty acids, hypertriglyceridemia and unfavorable adipocytokine profile[16]. However, few studies have shown the effective roles of genes involved in AT’s steroidogenesis in PCOS women and to our knowledge, the question of whether gene expression in AT of PCOS pregnant women may differ from that of non-PCOS pregnant women has not been addressed yet. One of the underlying hypotheses was expecting to see is difference in expression of HSD11B1 and HSD11B2 at the time of delivery to confirm the importance of cortisol metabolism at delivery day in PCOS mother. With this background, the current study aims to investigate the mRNA levels of fifteen steroids genes in subcutaneous AT in pregnant women.

2. Materials And Methods

2.1. Subjects and Adipose tissue biopsies
After obtaining permission from Royan Institute Ethics Committee, Tehran, Iran (IR.ACECR.ROYAN.REC.1398.087), samples and demographic data were collected from three hospitals in Tehran, Iran. The subjects were 48 Iranian pregnant women undergoing cesarean section, including 12 PCOS and 36 non–PCOS women, from whom subcutaneous AT samples were retrieved from the abdominal area. Signed informed consent was obtained from all subjects. During sampling, the following information was collected: age, weight (before pregnancy and at delivery day), height, gestational information, and habits such as smoking, specific nutritional practices and alcohol consumption using a written questionnaire. According to the guideline for the assessment and management of PCOS [17], the diagnostic traits of PCOS are the presence of two or more significant signs of syndrome and patients must meet two out of three signs. Diagnosis of PCOS in the enrolled subjects was the responsibility of the medical practitioner related to Royan Institute. Intake of any medication affecting glucose, lipid metabolism and diabetes, alcoholic consumption and smoking were defined as exclusion criteria. Reasons for delivery by caesarean section included maternal choice (< 10%), previous caesarean delivery and diagnosis by the medical practitioner.

At the time of caesarean section, the surgeon excised 3–4 g of subcutaneous AT upon exposing the abdominal cavity. The respective biopsies were immediately washed in isotonic saline solution, segmented and floated in liquid nitrogen, placed in cryovial tubes and snap-frozen. Samples were stored at liquid nitrogen (-196° C) until analysis [12].

2.2 RNA extraction, cDNA synthesis and qPCR procedures

Total RNA were extracted for all samples, using the RNeasy lipid tissue mini kit (QIAGEN, Germany) according to the manufacturer’s instructions. The integrity of the extracted RNA was evaluated using 1% agarose gels and stained with gel red, and the quality of extracted RNA was evaluated in terms of the A260/280 ratio using a spectrophotometer (Bio-Rad, Stanford, USA). Then, cDNA synthesis was performed on RNA samples using the PrimeScript RT Reagent Kit (TAKARA, Japan) according to the manufacturer’s instructions, in the way that all experiments included RT controls and negative controls (without cDNA). PCR products were analyzed by gel electrophoresis. mRNA quantification was performed by qRT-PCR on the Step-One RT-PCR system (Applied Biosystems, USA). Each reaction was run in duplicate. Primer design was performed for all fourteen steroids target genes using the Perl primer Software (version1.1.21) and the NCBI primer Blast. The primer sets, product size, and NIH GenBank accession numbers are listed in Table 1. To verify primer specificities, melting curve analyses were performed. Standard curves were obtained for each gene to evaluate primer efficiency using the logarithmic dilution series of total cDNA. The housekeeping gene GAPDH was used for normalization and messenger RNA expression levels of all target genes were analyzed by quantitative real-time PCR ($2^{-\Delta\Delta CT}$).

Table1. Sequences of the primers used for the quantification of the target genes (F: Forward; R: Revers)
| Gene       | NIH Gen Bank accession No. | Product length (bp) | Primer sequence 5´- 3´                        |
|------------|---------------------------|---------------------|----------------------------------------------|
| STAR       | NM:000349.2               | 114                 | GCCCAAGAGCATCATCAAC(F)                       |
|            |                           |                     | GCTGGTCTTCAACACCTG (R)                       |
| HSD11B1    | NM:001206741.1            | 180                 | GCAATTGGTGTCGTCTCTCT(T)                      |
|            |                           |                     | TGGCTGTTTCTGTGTCTATGAG(R)                    |
| HSD11B2    | NM:000196.3               | 162                 | GCTGTGAACCTCCTTCCCT(F)                       |
|            |                           |                     | CGATGTAGTCTTGGCCGT(R)                        |
| HSD17B2    | NM:002153.2               | 136                 | TCTGCTGCTCATCCTGT(F)                         |
|            |                           |                     | CAATCACCACCTGTCACCA(R)                       |
| HSD17B3    | NM:000197.1               | 138                 | ATGCTTCCAAACCTTCTCCC(F)                      |
|            |                           |                     | GAGACCTTTTTCTGGCTTATTCC(R)                   |
| AKR1C3     | NM:001253908.1            | 151                 | CTCCAGAGGTCCCGGAGA(A)                        |
|            |                           |                     | CTCTTCACACTGCCATCTG(R)                       |
| HSD17B7    | NM:001304512.1            | 112                 | TCATCTGTGTTTGGCGTG(F)                        |
|            |                           |                     | GTTGCTGACATCCACCTG(R)                        |
| HSD17B12   | NM:016142.2               | 113                 | CCTACCTAGGCTGTGGATT(F)                       |
|            |                           |                     | ACCTGTGACAAACTGCCC(A)                        |
| HSD3B1     | NM:000862.2               | 185                 | CTTGGTGAAGGAGAGAGGC(F)                       |
|            |                           |                     | AGGCCGTTGGATGATGAR(R)                        |
| HSD3B2     | NM:000198.3               | 173                 | TGCCAGTCTTCTGAGTCTCAACC(F)                   |
|            |                           |                     | TAGATTCCAACCATTAGCCG(R)                     |
| CYP17A1    | NM:000102.3               | 154                 | GATAACCACATTCTCAACCAC(F)                     |
|            |                           |                     | GGCTGAAACCACATTCTG(R)                        |
| CYP11A1    | NM:000781.2               | 169                 | CTTCCCTTCTGTCTCAATTCCC(F)                    |
|            |                           |                     | TCTACCAGATGTTCCACACC(R)                     |
| CYP21A2    | NM:000500.8               | 103                 | TGAAGCAGGCCCATAGAGAAG(F)                     |
|            |                           |                     | ATGTAGTCCATCATGTCCCTC(R)                     |
| HSD17B1    | NM:000413.3               | 234                 | TTCAGATCCATCCCAGAGC(F)                       |
|            |                           |                     | TTGATGTCCTTACGTCCAG(R)                       |
### 2.2. Statistical analysis

Data were initially tested for normal distribution using Kolmogorov-Smirnov test. Data with normal distribution were analyzed using *t* test. Data that did not have normal distribution were analyzed using Mann–Whitney U test. All analyses were conducted in SAS. The differences were considered significant at $P \leq 0.05$.

### 3. Results

#### 3.1. Characteristics of PCOS patients and non-PCOS pregnant women

No significant differences were found with respect to age, BMI (before pregnancy and at delivery day), gestational period and parity among non-PCOS and PCOS pregnant women (Table 2).

|                      | non-PCOS (n = 36) | PCOS (n = 12) | P-Value |
|----------------------|-------------------|---------------|---------|
| **Age (year)**       | 32 ± 5.7          | 31.6 ± 3.6    | ns.     |
| **BMI (kg m$^{-2}$) before pregnancy** | 25.4 ± 6.06  | 26.2 ± 6.11 | ns.     |
| **BMI (kg m$^{-2}$) at delivery day** | 31 ± 5.13   | 30.5 ± 5.74 | ns.     |
| **Gestation period (Day)** | 264 ± 13         | 267 ± 5      | ns.     |
| **Parity (no.)**    | 1.4 ± 0.62        | 1.4 ± 0.51    | ns.     |

#### 3.2. Profiling of the key steroidogenic genes in subcutaneous AT

The expression profile of key steroidogenic enzyme was compared in human AT obtained from PCOS and non-PCOS pregnant women (Table 3). mRNAs of *STAR* ($P < 0.001$) and *CYP11A1* ($P < 0.05$) – the genes involved in the initial steps of steroidogenesis – were significantly more abundant in the subcutaneous AT of PCOS women, than in those of non-PCOS women (Fig. 1). In addition, *CYP17A1* ($P < 0.05$) mRNA changed in the PCOS pregnant women, being significantly higher than that of non-PCOS pregnant women (Fig. 2). The mRNA encoding *11BHSD1* ($P < 0.05$) and *11BHSD2* ($P < 0.01$), the genes related to
glucocorticoids metabolism, were more abundant in PCOS than non-PCOS women (Fig. 3). In contrast, the expression of CYP21A2, the gene involved in the mineralocorticoids metabolism, was 4-fold higher in non-PCOS group than that in the PCOS group (Fig. 4; P < 0.001). There were no significant differences between relative expression of 3BHSD1 and 3BHSD2 (Fig. 2). There were also no differences between the groups in the expressions of genes related to sex steroid metabolism such as the CYP19A1, and 17BHSD families (1, 3, 5, 7, and 12) (Fig. 5). Expression of 17BHSD2 was undetectable in AT of both groups with the protocol used herein.

Table 3
Levels of mRNA in subcutaneous adipose tissue samples of PCOS (n = 12) relative to non-PCOS (n = 36) (ns.: non-significant)

| Gene    | Relative level | Fold difference | P-Value |
|---------|----------------|-----------------|---------|
| STAR    | PCOS > non-PCOS| 1.5             | < 0.001 |
| CYP11A1 | PCOS > non-PCOS| 1.3             | < 0.05  |
| HSD11B1 | PCOS > non-PCOS| 1.5             | < 0.05  |
| HSD11B2 | PCOS > non-PCOS| 1.63            | < 0.01  |
| CYP17A1 | PCOS > non-PCOS| 1.2             | < 0.05  |
| CYP21A2 | non-PCOS > PCOS| 4               | < 0.001 |
| HSD17B1 | PCOS > non-PCOS| 1.03            | ns.     |
| HSD17B3 | PCOS > non-PCOS| 1.05            | ns.     |
| AKR1C3  | non-PCOS > PCOS| 2.2             | ns.     |
| HSD17B7 | non-PCOS > PCOS| 1.02            | ns.     |
| HSD17B12| PCOS > non-PCOS| 1.09            | ns.     |
| HSD3B1  | PCOS > non-PCOS| 1.13            | ns.     |
| HSD3B2  | PCOS > non-PCOS| 2               | ns.     |
| CYP 19  | PCOS > non-PCOS| 1.02            | ns.     |
| HSD17B2 | undetectable   | -               | -       |

4. Discussion

It was reported that AT is equipped with a steroidogenic machinery for de novo synthesis from cholesterol, initiated by STAR and CYP11A1 [3]. Not only the total amount of steroids within AT was found to be 40–400 times greater than in plasma, but there also was a positive gradient between tissue and plasma [7]. It was suggested that both STAR and CYP11A1 are rate-limiting factors for steroidogenesis as they produce crucial precursors [3, 18]. Previous studies have shown the association
between CYP11A1 and PCOS [19]. For the first time in 2008, MacKenzie et al. identified STAR and CYP11A1 gene expression in paired visceral and subcutaneous AT from the lower abdominal region were taken from eight women undergoing caesarean section [12]. Likewise, Wang et al. (2012) showed expression of CYP11A1 in abdominal subcutaneous AT taken from non-pregnant women [7]. Although Alizadeh et al. reported that CYP11A1 mRNA was not detectable in retroperitoneal and subcutaneous dairy cattle AT [20], they showed that the amount of STAR mRNA in subcutaneous AT on the day of delivery was 3-fold higher than before calving. The up-regulation of genes involved in initial steps of steriodogenes on the day of delivery in PCOS mothers indicate an increase capacity for cholesterol uptake to the inner mitochondrial membrane and steriodogenesis stimulation. These data provide evidence that PCOS women may have more functional and effective sources of steroid metabolism pathways in subcutaneous AT on the day of delivery than age- and BMI-matched non-PCOS women.

CYP17A1 is a key branch point in steroid biosynthesis, driving the pathway to the direction of either mineralocorticoid and glucocorticoid production or sex steroid metabolism [21]. Wickenheisser et al. reported that CYP17A1 mRNA was more abundant in ovarian theca cells of PCOS than non-PCOS women [21, 22]. In the current study, CYP17A1 was transcribed higher in subcutaneous AT of PCOS than non-PCOS women. MacKenzie et al. did not detect this gene in subcutaneous AT on the day of delivery, and neither did Valle et al. in non-pregnant women and men [12, 23]. However, the presence of CYP17A1 gene in PCOS women's subcutaneous AT was reported by Wang et al. in 2012. Uniquely, Kinoshita et al. using an innovative liquid chromatography–mass spectrometry (LC-MS/MS)-based method could detect CYP17A1 at the protein level [24]. A potential for up-regulation of CYP17A1 expression in AT was proposed, which may contribute to hyperandrogenism in women suffering from PCOS [25–27]. Therefore, our data for CYP17A1 support the hypothesis [27] that confirms the overexpression of this gene that plays a crucial role in PCOS pregnant women, which may be related to the regulation of glucocorticoid as well as mineralocorticoids metabolism.

Among fourteen genes that we detected and compared among both groups, relative expression of CYP21 was 4-fold higher in non-PCOS than in PCOS. Similarly, Azziz et al. [28] and Witchel and Aston [29] showed the deficiency of 21-hydroxylase in hirsute women with PCOS. One of the main steps in adrenal and ovarian steroidogenesis is the conversion of 17-hydroxyprogesterone into 11-deoxycortisol, which is catalyzed by the 21-hydroxylase enzyme encoded by CYP21. The deficiency of this enzyme, which is inherited by an autosomal recessive trait, is responsible for most cases of congenital adrenal hyperplasia and increased serum 17-hydroxyprogesterone levels are correlated with its deficiency. Furthermore, patients suffering from heterozygote CYP21 mutations as well as clinical symptoms exhibit PCOS-like phenotype [30]. Therefore, the changes in amounts of CYP21 mRNA support the above reasoning.

Our data confirmed the findings of previous studies that HSD11B1 and HSD11B2 mRNA are present in both subjects and are also more in subcutaneous AT of PCOS than non-PCOS. In the same study, 42 women with PCOS with a broad range of BMI were studied and it was shown that in these women, there was increased HSD11B1 enzyme activity with increasing central fat distribution [31]. This could indicate impaired HSD11B1 activity in women with PCOS compared with control.
Due to cortisol peak and critical roles of cortisol around delivery day, more attention must be paid to cortisol metabolism. Previously, the expression of \textit{HSD11B1} in human AT, particularly in visceral fat, has been confirmed \cite{32}. Makenzie et al suggested high expression of \textit{HSD11B1} gene in both subcutaneous and visceral AT on the day of delivery \cite{12}. Based on the evidence for \textit{HSD11B1} in human AT and bovine AT from different visceral and subcutaneous depots, AT likely affects glucocorticoid metabolism with consequences for both endocrine as well as auto/paracrine glucocorticoid effects locally within AT, the latter being supported by the presence of glucocorticoid receptors, also demonstrated in bovine AT \cite{12, 33}. In this regard, Alizadeh et al (2016 b) studied the presence of \textit{HSD11B1} mRNA in dairy cattle AT around calving day. They showed that the highest expression of \textit{HSD11B1} in bovine AT was shown on the day of delivery rather the days before and after calving \cite{34}. Therefore, the elevation of cortisol metabolism around parturition is normal; but our study clearly showed 1.5-fold elevation of \textit{HSD11B1} mRNA levels in PCOS over non-PCOS. Similarly, Corto´n et al. reported that non-pregnant PCOS women had up regulation of \textit{HSD11B1} expression in abdominal subcutaneous AT compared to non-PCOS ones, which is consistent with our data \cite{35}. Although the elevation of \textit{HSD11B1} in obesity has been reported, it was surprising to note that the alarming increase in BMI-matched subject incidence of AT importance is associated with an array of metabolic pathologies, including PCOS.

The presence of \textit{CYP19} (aromatase) mRNA in human AT has already been well established by Corbould et al \cite{36} and Makenzi et al \cite{12}. Although it has been proposed that PCOS may result from reduced aromatase activity and subcutaneous AT have higher expression of \textit{Cyp19a1} compared to visceral AT in morbidly obese men and premenopausal women \cite{37}, we cannot find difference in mRNA levels of \textit{CYP19} between PCOS and non-PCOS women. Previously, the conversion of androstenedione to estrone in subcutaneous AT from the lower body of women (i.e., thighs and buttocks) was shown to be higher than that of in the subcutaneous AT of upper body fat (i.e., breast and abdomen), along with the highest level of \textit{Cyp19a1} gene expression \cite{38}. Altogether, the absence of changes in \textit{Cyp19a1} suggest that delivery day or sampling area may influence \textit{CYP19} expression than PCOS.

Enzymes with activities associated with various \textit{17BHSD} isoforms are widespread, not only in classic steroidogenic tissues such as the testis, ovary, and placenta but also in a large number of peripheral sites including AT \cite{39}. The estrogenic isoforms of \textit{17BHSD} (types 1, 7 and 12) catalyze the conversion of estrone to estradiol \cite{3} and they are similar in PCOS and non-PCOS groups in the current study. The \textit{17BHSD} family genes involved in the estrogenic process in AT are much fewer than those of the androgenic one, inferring that subcutaneous AT may serve as a dominant activation site for androgens than estrogens. Bellemare et al. (2009) suggested that type 12 \textit{17BHSD} is probably involved in the local conversion of estrone into estradiol in differentiated adipocytes and it has more activity than other isoforms \cite{40}. Uniquely, Quinkler et al showed that \textit{17BHSD5} has pivotal roles in women androgen metabolism in subcutaneous buttock AT \cite{11}. Therefore, we expected that \textit{17BHSD5} and type 12 \textit{17BHSD} may differ between experimental groups; but our findings did not support the hypotheses regarding different sex steroid related gene expression in subcutaneous AT.
It appears that sampling area (buttock AT vs. abdominal AT) may influence these results; but the mRNA levels of $17\beta$HSD5 were 2-folds higher in abdominal subcutaneous AT of PCOS women compared to the non-PCOS women [7]. So, this result may affect the status on the day of delivery, as shown by Mackenzie et al. [12]. They suggested that de novo synthesis of sex steroids from cholesterol is not possible in pregnant women on the day of delivery because of the absence of key steroidogenic mRNAs in the AT.

Finally, the survey on PCOS mother and offspring health is an exciting and emerging area for research and clinical studies. Uniquely, Kosidou et al. [41] reported that children of mothers with PCOS have an increased risk of developing autism spectrum disorder and their findings support that early life androgen exposure may be important for the development of autism in both sexes which it was supported by Katsigianni et al [42]. These reports alongside our data suggest further studies are warranted in order to shed more light on of AT’s roles in PCOS mother.

Our study has a few limitations that must be considered when interpreting our results. AT samples are not easily available. Therefore, small sample size was the limitation of this study for age- and BMI- matched PCOS women. It would have been interesting to compare expression with non-pregnant women or across gestation and additional studies with larger sample sizes could confirm these results in pregnant and non-pregnant PCOS women alongside measured several hormone levels. Other factors such as fat distribution may be related to the differences observed.

5. Conclusion

In conclusion, our data showed that in AT of pregnant women suffering from PCOS, the genes related to initial steps of steroidogenesis ($\text{STAR}$ and $\text{CYP11A1}$) were more expressed compared to age- and BMI- matched non-PCOS women. The expression levels of genes related to cortisol metabolism ($1\beta$HSD1 and $1\beta$HSD2) were higher in PCOS women than age- and BMI- matched non-PCOS, the profile which may be due to the regulation of glucocorticoid metabolism. This finding opens the door to further assessment of the critical roles of AT in cortisol metabolism in PCOS mothers. Moreover, dramatic decrease of $\text{CYP21}$ mRNA confirms gene expression disorders in mineralocorticoid metabolism for PCOS women. Altogether, the alterations in gene expressions involved in glucocorticoids and mineralocorticoid metabolism was shown which warrants further studies regards functional activity.

Abbreviations

AT: adipose tissue; PCOS: polycystic ovary syndrome; $17\beta$HSD: $17\beta$-Hydroxysteroid dehydrogenases; $\text{STAR}$: steroidogenic acute regulator; $\text{CYP11A1}$: cytochrome P450 monooxygenase; $\text{CYP17A1}$: $17\alpha$-hydroxylase; $11\beta$HSD: 11$\beta$-Hydroxysteroid dehydrogenase; $\text{CYP21}$: steroid 21-hydroxylase; $\text{CYP19A1}$: cytochrome P450 aromatase; $3\beta$HSD: 3$\beta$-hydroxysteroid dehydrogenase.

Declarations
Ethical Approval and Consent to participate

After obtaining permission from Royan Institute Ethics Committee, Tehran, Iran (IR.ACECR.ROYAN.REC.1398.087), samples and demographic data were collected from three hospitals in Tehran, Iran. Signed informed consent was obtained from all subjects.

Consent for publication

This manuscript did not contain any individual person's data in any form (including any individual details, images or videos).

Availability of data and material

All data and material used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This project was part of a PhD dissertation and supported by Royan Institute, Tehran, Iran and Islamic Azad University, Science and Research Branch, Tehran, Iran (Research contract no. 96/19/3279).

Authors' contributions

NE PhD. student, Main project contributor, Investigation, Data analysis, Writing- Original draft preparation, Visualization. AM Project advisor, Methodology and participants selection, Resources, Writing - review & editing. PY Project advisor, Investigation, Methodology, Writing - review & editing. VA Methodology, Data analysis, Writing - review & editing. MS Projects supervisor, Methodology, Validation, Writing and Reviewing, Visualization. AA Projects supervisor, Project management, Validation, Writing and Reviewing, Visualization. All authors have read and approved the final manuscript.

Acknowledgments

We thank all participants who took part in our study. We also would like to thank Royan Institute laboratory staffs for assisted in laboratory procedures. We also thank the surgical team at several hospitals for assistance with biopsy collection.

References

1. Lim S, Kakoly N, Tan J, Fitzgerald G, Bahri Khomami M, Joham A, Cooray S, Misso M, Norman R, Harrison C. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis
1. and meta-regression. Obesity reviews. 2019;20:339–52.

2. Schiffer L, Arlt W, O’Reilly MW: Understanding the role of androgen action in female adipose tissue. In Hyperandrogenism in Women. Volume 53: Karger Publishers; 2019: 33–49.

3. Li J, Papadopoulos V, Vihma V. Steroid biosynthesis in adipose tissue. Steroids. 2015;103:89–104.

4. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156:20–44.

5. Blouin K, Veilleux A, Luu-The V, Tchernof A. Androgen metabolism in adipose tissue: recent advances. Molecular cellular endocrinology. 2009;301:97–103.

6. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007;31:8–13.

7. Wang L, Li S, Zhao A, Tao T, Mao X, Zhang P, Liu W. The expression of sex steroid synthesis and inactivation enzymes in subcutaneous adipose tissue of PCOS patients. J Steroid Biochem Mol Biol. 2012;132:120–6.

8. Petry C, Ong K, Michelmore K, Artigas S, Wingate D, Balen A, de Zegher F, Ibanez L, Dunger D. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod. 2005;20:1837–43.

9. Belanger C, Dupont P, Tchernof A. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Hormone metabolic research. 2002;34:737–45.

10. Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Curr Med Chem. 2007;14:2918–24.

11. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity—a site-specific role for 17β-hydroxysteroid dehydrogenase type 5. J Endocrinol. 2004;183:331–42.

12. MacKenzie SM, Huda SS, Sattar N, Fraser R, Connell JM, Davies E. Depot-specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol. 2008;69:848–54.

13. Douchi T, Kuwahata R, Yamamoto S, Oki T, Yamasaki H, Nagata Y. Relationship of upper body obesity to menstrual disorders. Acta obstetricia et gynecologica Scandinavica. 2002;81:147–50.

14. Kuchenbecker WK, Groen H, Zijlstra TM, Bolster JH, Slart RH, van der Jagt EJ, Muller Kobold AC, Wolffsenbuttel BH, Land JA, Hoek A. The subcutaneous abdominal fat and not the intraabdominal fat compartment is associated with anovulation in women with obesity and infertility. The Journal of Clinical Endocrinology Metabolism. 2010;95:2107–12.

15. Yucel A, Noyan V, Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. European Journal of Obstetrics Gynecology Reproductive Biology. 2006;126:81–6.

16. Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS biology 2008, 6.
17. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110:364–79.

18. LaVoie HA, King SR. Transcriptional regulation of steroidogenic genes: STARD1, CYP11A1 and HSD3B. Experimental biology medicine. 2009;234:880–907.

19. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. PPAR Res. 2007;2007:49109.

20. Alizadeh A, Sadri H, Rehage J, Dănicie S, Sauerwein H. 1149 Expression of genes involved in the initial steps of steroidogenesis in adipose tissue depots of dairy cows during the dry period and early lactation. J Anim Sci. 2016a;94:551–2.

21. Gilep AA, Sushko TA, Usanov SA. At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochimica et Biophysica Acta (BBA)-Proteins Proteomics. 2011;1814:200–9.

22. Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Human ovarian theca cells in culture. Trends in Endocrinology Metabolism. 2006;17:65–71.

23. Dalla Valle L, Toffolo V, Nardi A, Fiore C, Bernante P, Di Liddo R, Parnigotto P, Colombo LJJoe. Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. 2006, 190:129–139.

24. Kinoshita T, Honma S, Shibata Y, Yamashita K, Watanabe Y, Maekubo H, Okuyama M, Takashima A, Takeshita N. An innovative LC-MS/MS-based method for determining CYP 17 and CYP 19 activity in the adipose tissue of pre-and postmenopausal and ovariectomized women using 13C-labeled steroid substrates. The Journal of Clinical Endocrinology Metabolism. 2014;99:1339–47.

25. Chazenbalk G, Chen Y-H, Heneidi S, Lee J-M, Pall M, Chen Y-DI, Azziz R. Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. The Journal of Clinical Endocrinology. 2012;97:E765–70.

26. Jones MR, Chazenbalk G, Xu N, Chua AK, Eigler T, Mengesha E, Chen Y-H, Lee J-M, Pall M, Li X. Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility. The Journal of Clinical Endocrinology Metabolism. 2012;97:E1750–7.

27. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature reviews endocrinology. 2011;7:219.

28. Azziz R, Sanchez L, Knochenhauer E, Moran C, Lazenby J, Stephens K, Taylor K, Boots L. Androgen excess in women: experience with over 1000 consecutive patients. The Journal of Clinical Endocrinology Metabolism. 2004;89:453–62.

29. Witchel S, Aston C. The role of heterozygosity for CYP21 in the polycystic ovary syndrome. Journal of pediatric endocrinology metabolism: JPEM. 2000;13:1315–7. PMID: 11117678.
30. Papadopoulos V, Berkovich A, Krueger K, Costa E, Guidotti A. Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. Endocrinology. 1991;129:1481–8.

31. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5α-reduction but not the elevated adrenal steroid production rates. The Journal of Clinical Endocrinology Metabolism. 2003;88:5907–13.

32. Stulnig T, Waldhäusl W. 11β-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia. 2004;47:1–11.

33. Friedauer K, Dänicke S, Schulz K, Sauerwein H, Häussler S. Detection of 11 beta-hydroxysteroid dehydrogenase type 1, the glucocorticoid and mineralocorticoid receptor in various adipose tissue depots of dairy cows supplemented with conjugated linoleic acids. J Anim Physiol Anim Nutr (Berl). 2015;99:950–61.

34. Alizadeh A, Sadri H, Rehage J, Dänicke S, Sauerwein H: Expression of 11β-HSD1 mRNA in adipose tissue of dairy cows during the periparturient period. In 67th Annual Meeting of the European Federation of Animal Science - EAAP 2016. pp. 676. Belfast, United Kingdom: Wageningen Academic Publishers; 2016b:676.

35. Cortón M, Botella-Carretero JI, Benguria A, Villuendas G, Zaballos A, San Millán JL, Escobar-Morreale HF, Peral B. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology Metabolism. 2007;92:328–37.

36. Corbould A, Bawden M, Lavranos T, Rodgers R, Judd S. The effect of obesity on the ratio of type 3 17β-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int J Obes. 2002;26:165–75.

37. Wang F, Vihma V, Soronen J, Turpeinen U, Hämäläinen E, Savolainen-Peltonen H, Mikkola TS, Naukkarinen J, Pietiläinen KH, Jauhiainen M. 17β-Estradiol and estradiol fatty acyl esters and estrogen-converting enzyme expression in adipose tissue in obese men and women. The Journal of Clinical Endocrinology Metabolism. 2013;98:4923–31.

38. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab. 1994;78:428–32. PMID: 8106632.

39. Molaie S, Shahverdi A, Sharafi M, Shahhoseini M, Rashki Ghaleno L, Esmaeili V, Abed-Heydari E, Numan Bucak M, Alizadeh A. Dietary trans and saturated fatty acids effects on semen quality, hormonal levels and expression of genes related to steroid metabolism in mouse adipose tissue. Andrologia. 2019;51:e13259.

40. Bellemare V, Laberge P, Noël S, Tchernof A, Luu-The V. Differential estrogenic 17β-hydroxysteroid dehydrogenase activity and type 12 17β-hydroxysteroid dehydrogenase expression levels in preadipocytes and differentiated adipocytes. J Steroid Biochem Mol Biol. 2009;114:129–34.
41. Kosidou K, Dalman C, Widman L, Arver S, Lee B, Magnusson C, Gardner R. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Molecular psychiatry. 2016;21:1441–8.

42. Katsigianni M, Karageorgiou V, Lambrinoudaki I, Siristatidis C. Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2019;24:1787–97.

**Figures**

**Figure 1**

mRNA relative expression of the key enzymes involved in the initial steps of steroidogenesis in adipose tissue based on qRT-PCR in non-PCOS pregnant women (n=36) and PCOS (n = 12) pregnant women.
**Figure 2**

mRNA relative expression of CYP17, 3BHSD1 and 3BHSD2 in adipose tissue based on qRT-PCR in non-PCOS pregnant women (n=36) and PCOS (n = 12) pregnant women.
Figure 3

mRNA relative expression of 11BHSD1 and 11BHSD2 which related to glucocorticoids metabolism in adipose tissue based on qRT-PCR in non-PCOS pregnant women (n=36) and PCOS (n = 12) pregnant women.
Figure 4

mRNA relative expression of CYP21 which related to mineralocorticoids metabolism in adipose tissue based on qRT-PCR in non-PCOS pregnant women (n=36) and PCOS (n = 12) pregnant women.
Figure 5

mRNA relative expression of genes involved in sex steroid metabolism in adipose tissue based on qRT-PCR in non-PCOS pregnant women (n=36) and PCOS (n = 12) pregnant women.